Suberanilohydroxamic Acid. Aton Pharma.
Aton Pharma Inc, under license from the Memorial Sloan-Kettering Cancer Center, is developing suberanilohydroxamic acid (SAHA), a cytodifferentiating agent and histone deacetylase inhibitor, as a potential cancer chemopreventive.